Evidence and desperation in off-label prescribing: recombinant factor VIIa
23 June 2014Wendy Lipworth and colleagues explore why clinicians prescribe recombinant f actor VIIa off-label for major haemorrhage, despite a lack of supporting evidence—and why this matters